OraSure Technologies (NASDAQ: OSUR) reported Q2 EPS of $0.07, $0.03 better than the analyst estimate of $0.04. Revenue for the quarter came in at $43.6 million versus the consensus estimate of $42.23 million.

“Our financial results for the second quarter of 2018 exceeded expectations and continued the solid performance started in Q1,” said Dr. Stephen S. Tang, President and CEO of OraSure Technologies. “Continued strong international sales of our HIV Self-Test and another strong quarter by our molecular collections business were the primary drivers of this performance. We expect that our HIV Self-Test and molecular businesses will continue to be key growth contributors for the rest of 2018.”

GUIDANCE:

OraSure Technologies sees Q3 2018 EPS of $0.10-$0.12, versus the consensus of $0.11. OraSure Technologies sees Q3 2018 revenue of $44-45.5 million, versus the consensus of $44.17 million.

For earnings history and earnings-related data on OraSure Technologies (OSUR) click here.